Doravirine

Doravirine (MK-1439) is a non-nucleoside reverse transcriptase inhibitor developed by Merck & Co. for use in the treatment of HIV/AIDS. In August 2018, the FDA approved doravine under the product name Pifeltro, and in a combination tablet, doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo).